Cargando…
Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats
Myocardial ischemia-reperfusion (IR) injury contributes to adverse cardiac outcomes after myocardial ischemia, cardiac surgery, or circulatory arrest. In this study, we evaluated the ability of combined SS31-mitochondria (Mito) therapy to protect heart cells from myocardial IR injury. Adult male SD...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164143/ https://www.ncbi.nlm.nih.gov/pubmed/30223594 http://dx.doi.org/10.3390/ijms19092782 |
_version_ | 1783359530034266112 |
---|---|
author | Lee, Fan-Yen Shao, Pei-Lin Wallace, Christopher Glenn Chua, Sarah Sung, Pei-Hsun Ko, Sheung-Fat Chai, Han-Tan Chung, Sheng-Ying Chen, Kuan-Hung Lu, Hung-I Chen, Yi-Ling Huang, Tien-Hung Sheu, Jiunn-Jye Yip, Hon-Kan |
author_facet | Lee, Fan-Yen Shao, Pei-Lin Wallace, Christopher Glenn Chua, Sarah Sung, Pei-Hsun Ko, Sheung-Fat Chai, Han-Tan Chung, Sheng-Ying Chen, Kuan-Hung Lu, Hung-I Chen, Yi-Ling Huang, Tien-Hung Sheu, Jiunn-Jye Yip, Hon-Kan |
author_sort | Lee, Fan-Yen |
collection | PubMed |
description | Myocardial ischemia-reperfusion (IR) injury contributes to adverse cardiac outcomes after myocardial ischemia, cardiac surgery, or circulatory arrest. In this study, we evaluated the ability of combined SS31-mitochondria (Mito) therapy to protect heart cells from myocardial IR injury. Adult male SD rats (n = 8/each group) were randomized: group 1 (sham-operated control), group 2 (IR, 30-min ischemia/72 h reperfusion), group 3 (IR-SS31 (2 mg intra-peritoneal injection at 30 min/24 h/48 h after IR)), group 4 (IR-mitochondria (2 mg/derived from donor liver/intra-venous administration/30 min after IR procedure)), and group 5 (IR-SS31-mitochondria). In H9C2 cells, SS31 suppressed menadione-induced oxidative-stress markers (NOX-1, NOX-2, oxidized protein) while it increased SIRT1/SIRT3 expression and ATP levels. In adult male rats 72 h after IR, left ventricular ejection fraction (LVEF) was highest in sham-operated control animals and lowest in the IR group. LVEF was also higher in IR rats treated with SS31-Mito than untreated IR rats or those treated with Mito or SS31 alone. Areas of fibrosis/collagen-deposition showed the opposite pattern. Likewise, levels of oxidative-stress markers (NOX-1, NOX-2, oxidized protein), inflammatory markers (MMP-9, CD11, IL-1β, TNF-α), apoptotic markers (mitochondrial-Bax, cleaved-caspase-3, PARP), fibrosis markers (p-Smad3, TGF-β), DNA-damage (γ-H2AX), sarcomere-length, and pressure/volume overload markers (BNP, β-MHC) all showed a pattern opposite that of LVEF. Conversely, anti-apoptotic (BMP-2, Smad1/5) and energy integrity (PGC-1α/mitochondrial cytochrome-C) markers exhibited a pattern identical to that of LVEF. This study demonstrates that the combined SS31-Mito therapy is superior to either therapy alone for protecting myocardium from IR injury and indicates that the responsible mechanisms involved increased SIRT1/SIRT3 expression, which suppresses inflammation and oxidative stress and protects mitochondrial integrity. |
format | Online Article Text |
id | pubmed-6164143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61641432018-10-10 Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats Lee, Fan-Yen Shao, Pei-Lin Wallace, Christopher Glenn Chua, Sarah Sung, Pei-Hsun Ko, Sheung-Fat Chai, Han-Tan Chung, Sheng-Ying Chen, Kuan-Hung Lu, Hung-I Chen, Yi-Ling Huang, Tien-Hung Sheu, Jiunn-Jye Yip, Hon-Kan Int J Mol Sci Article Myocardial ischemia-reperfusion (IR) injury contributes to adverse cardiac outcomes after myocardial ischemia, cardiac surgery, or circulatory arrest. In this study, we evaluated the ability of combined SS31-mitochondria (Mito) therapy to protect heart cells from myocardial IR injury. Adult male SD rats (n = 8/each group) were randomized: group 1 (sham-operated control), group 2 (IR, 30-min ischemia/72 h reperfusion), group 3 (IR-SS31 (2 mg intra-peritoneal injection at 30 min/24 h/48 h after IR)), group 4 (IR-mitochondria (2 mg/derived from donor liver/intra-venous administration/30 min after IR procedure)), and group 5 (IR-SS31-mitochondria). In H9C2 cells, SS31 suppressed menadione-induced oxidative-stress markers (NOX-1, NOX-2, oxidized protein) while it increased SIRT1/SIRT3 expression and ATP levels. In adult male rats 72 h after IR, left ventricular ejection fraction (LVEF) was highest in sham-operated control animals and lowest in the IR group. LVEF was also higher in IR rats treated with SS31-Mito than untreated IR rats or those treated with Mito or SS31 alone. Areas of fibrosis/collagen-deposition showed the opposite pattern. Likewise, levels of oxidative-stress markers (NOX-1, NOX-2, oxidized protein), inflammatory markers (MMP-9, CD11, IL-1β, TNF-α), apoptotic markers (mitochondrial-Bax, cleaved-caspase-3, PARP), fibrosis markers (p-Smad3, TGF-β), DNA-damage (γ-H2AX), sarcomere-length, and pressure/volume overload markers (BNP, β-MHC) all showed a pattern opposite that of LVEF. Conversely, anti-apoptotic (BMP-2, Smad1/5) and energy integrity (PGC-1α/mitochondrial cytochrome-C) markers exhibited a pattern identical to that of LVEF. This study demonstrates that the combined SS31-Mito therapy is superior to either therapy alone for protecting myocardium from IR injury and indicates that the responsible mechanisms involved increased SIRT1/SIRT3 expression, which suppresses inflammation and oxidative stress and protects mitochondrial integrity. MDPI 2018-09-15 /pmc/articles/PMC6164143/ /pubmed/30223594 http://dx.doi.org/10.3390/ijms19092782 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lee, Fan-Yen Shao, Pei-Lin Wallace, Christopher Glenn Chua, Sarah Sung, Pei-Hsun Ko, Sheung-Fat Chai, Han-Tan Chung, Sheng-Ying Chen, Kuan-Hung Lu, Hung-I Chen, Yi-Ling Huang, Tien-Hung Sheu, Jiunn-Jye Yip, Hon-Kan Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats |
title | Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats |
title_full | Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats |
title_fullStr | Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats |
title_full_unstemmed | Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats |
title_short | Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats |
title_sort | combined therapy with ss31 and mitochondria mitigates myocardial ischemia-reperfusion injury in rats |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164143/ https://www.ncbi.nlm.nih.gov/pubmed/30223594 http://dx.doi.org/10.3390/ijms19092782 |
work_keys_str_mv | AT leefanyen combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats AT shaopeilin combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats AT wallacechristopherglenn combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats AT chuasarah combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats AT sungpeihsun combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats AT kosheungfat combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats AT chaihantan combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats AT chungshengying combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats AT chenkuanhung combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats AT luhungi combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats AT chenyiling combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats AT huangtienhung combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats AT sheujiunnjye combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats AT yiphonkan combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats |